PX1 Research provides researchers and laboratories with analytical-grade CJC-1295 No DAC (Modified GRF 1-29) synthesized in USA-based facilities. Every batch undergoes rigorous RP-HPLC purity testing and mass spectrometry verification to guarantee maximum stability and reproducibility in preclinical model systems.
PX1 Research provides researchers and laboratories with analytical-grade CJC-1295 No DAC (Modified GRF 1-29) synthesized in USA-based facilities. Every batch undergoes rigorous RP-HPLC purity testing and mass spectrometry verification to guarantee maximum stability and reproducibility in preclinical model systems.
To buy CJC-1295 No DAC (Mod GRF 1-29) for laboratory research, investigators must select suppliers providing verified purity (>99% by RP-HPLC), mass spectrometry validation, and lot-specific Certificates of Analysis. CJC-1295 No DAC is a 29-amino acid synthetic growth hormone-releasing hormone (GHRH) analog optimized for enhanced plasma stability while retaining natural pulsatile somatotroph signaling.
When purchasing reagents for secretagogue evaluation, research institutions require strict analytical validation. PX1 Research synthesizes buy CJC-1295 No DAC under stringent Quality Management Systems (QMS) in state-of-the-art domestic facilities. Each vial is freeze-dried under aseptic conditions to ensure structural integrity and consistent bioactivity across cellular assays and animal models.
Endogenous Growth Hormone Releasing Hormone (GHRH 1-44) is rapidly degraded in vivo by dipeptidyl peptidase IV (DPP-IV), which cleaves the N-terminal Ala2 position within minutes. Early truncation to GHRH 1-29 (Sermorelin) preserved receptor binding affinity but maintained a short biological half-life (~8–12 minutes) in preclinical subjects.
Modified GRF 1-29 (often referenced as CJC-1295 No DAC) incorporates four specific amino acid substitutions to resist enzymatic cleavage and improve conformational stability: D-Ala2, Gln8, Ala15, and Leu27. By substituting D-alanine at position 2, the peptide resists DPP-IV enzymatic cleavage. The Gln8, Ala15, and Leu27 modifications stabilize the alpha-helical secondary structure, preventing oxidation and metabolic inactivation during experimental incubations.
Because Mod GRF 1-29 omits the Drug Affinity Complex (DAC)—a Lys-linker attached to a maleimido-propionic acid group that binds serum albumin—it exhibits rapid clearance relative to CJC-1295 DAC. This non-DAC modification allows researchers to precisely control time-course kinetics and examine physiological, pulsatile growth hormone (GH) secretion profiles without inducing sustained baseline elevations.
In vitro signaling studies demonstrate that CJC-1295 No DAC functions as a potent full agonist at the GHRH receptor (GHRHR), a class B G-protein-coupled receptor located on pituitary somatotrophs. Binding of Mod GRF 1-29 to GHRHR activates the Gs alpha subunit, stimulating transmembrane adenylyl cyclase activity and triggering an intracellular surge of cyclic adenosine monophosphate (cAMP).
Elevated cAMP levels activate protein kinase A (PKA), which phosphorylates the cAMP response element-binding protein (CREB). This signaling cascade drives transcription of the growth hormone gene while simultaneously opening L-type voltage-gated calcium channels. The influx of intracellular calcium induces exocytosis of pre-stored GH secretory granules.
Preclinical studies suggest that this pathway restores or amplifies physiological GH pulses. Unlike continuous GHRH stimulation, which can cause receptor desensitization and down-regulation, the transient half-life (~30 minutes) of Mod GRF 1-29 mimics endogenous neuroendocrine rhythmicity. Investigators studying GHRH receptor analogs rely on this controlled kinetic window to map endocrine feedback loops and pituitary responsiveness.
A critical distinction in secretagogue literature lies between CJC-1295 without DAC (Mod GRF 1-29) and CJC-1295 with DAC. The addition of the Drug Affinity Complex allows the peptide to form a covalent bond with circulating serum albumin via a reactive maleimide moiety. This extends the biological half-life to 6–8 days in mammalian models, maintaining elevated serum GH and insulin-like growth factor 1 (IGF-1) continuously.
While continuous elevation is useful for long-duration metabolic assays, it abolishes normal circadian GH peaks and alters natural somatostatin feedback mechanisms. For detailed pharmacokinetic comparisons, consult our CJC-1295 DAC vs No DAC comparison documentation.
Conversely, CJC-1295 No DAC clears within approximately 30–60 minutes post-administration in rodent models. This short half-life preserves discrete GH pulses and prevents the physiological suppression often observed with prolonged, non-pulsatile receptor saturation. Researchers seeking to isolate individual pulse amplitudes and monitor precise upstream or downstream gene expression profiles overwhelmingly select the No DAC modification.
Preclinical investigations frequently evaluate the synergistic co-administration of GHRH analogs with Growth Hormone Secretagogue Receptor (GHSR-1a) agonists, such as Growth Hormone Releasing Peptides (GHRPs). While GHRH analogs activate the cAMP/PKA pathway, GHSR-1a agonists operate via the phospholipase C (PLC) and inositol trisphosphate (IP3) pathways to release intracellular calcium stores.
When CJC-1295 No DAC is co-incubated or co-administered with ghrelin mimetics like Ipamorelin, GHRP-2, or GHRP-6, the combined GH release is significantly greater than the mathematical sum of either compound administered individually. This synergistic amplification occurs because intracellular cAMP and IP3/calcium pathways converge on distinct regulation points of the secretory granule machinery.
Comparative assays also include first-generation GHRH fragments like Sermorelin. However, Mod GRF 1-29 demonstrates superior metabolic resistance in vitro due to its tetrasubstituted design, requiring lower molar concentrations to achieve equivalent somatotroph activation.
In laboratory models evaluating tissue regeneration, cellular proliferation, and protein synthesis, sustained physiological levels of GH and downstream IGF-1 play pivotal roles. Preclinical rodent models administered Mod GRF 1-29 demonstrate measurable increases in hepatic IGF-1 mRNA expression and serum IGF-1 protein concentrations within hours of exposure.
In vitro assays using osteoblasts, chondrocytes, and myoblasts indicate that GH and IGF-1 signaling cascades stimulate collagen deposition, extracellular matrix remodeling, and nitrogen retention. In rodent models of musculoskeletal injury, GHRH analog administration has been correlated with accelerated satellite cell recruitment and enhanced myofibrillar repair.
Furthermore, animal models investigating metabolic homeostasis show that Mod GRF 1-29 administration modulates lipolysis in adipose tissue by upregulating hormone-sensitive lipase (HSL) activity without inducing systemic insulin resistance when pulsed correctly. These findings make CJC-1295 No DAC a primary reference material for endocrinology, sarcopenia, and wound healing research.
The integrity of experimental outcomes depends entirely on chemical purity and sequence accuracy. In superior peptide synthesis, non-target truncated sequences, stereoisomers, and residual trifluoroacetic acid (TFA) salts can interfere with cellular assays, leading to skewed receptor affinity measurements or false-positive cytotoxic responses.
PX1 Research enforces comprehensive quality control standards for every batch of CJC-1295 No DAC. Every lot undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity levels exceeding 99.0%. Sequence identification and molecular weight validation are performed via Electrospray Ionization Mass Spectrometry (ESI-MS). Learn more about our validation methodology in our guide on HPLC purity verification.
Additionally, because bacterial endotoxins can provoke non-specific inflammatory signaling in cell cultures and animal models, all PX1 Research products undergo chromogenic Limulus Amebocyte Lysate (LAL) endotoxin testing. We guarantee endotoxin levels below 0.5 EU/mg, protecting assay validity and preventing premature cell line apoptosis.
Lyophilized CJC-1295 No DAC should be stored upon arrival at -20°C for short-term projects or -80°C for long-term storage to prevent peptide hydrolysis or beta-sheet aggregation. Vials should be kept away from light and direct moisture.
Prior to reconstituting, the vial should be allowed to equilibrate to room temperature to prevent condensation inside the container. Reconstitution should be performed using sterile laboratory-grade solvents, such as Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline, depending on the specific protocol requirements. For step-by-step laboratory guidelines, reference our technical manual on reconstitution and storage protocols.
When adding solvent, gently direct the liquid stream down the glass container wall rather than directly onto the lyophilized cake. Allow the cake to dissolve naturally or rotate the vial gently. Never vortex or vigorously agitate the vial, as shear forces can disrupt the peptide's secondary structure. Reconstituted aliquots should be stored at 2°C to 8°C and utilized within 21 to 28 days.
Securing compliant, analytical-grade compounds is critical for research institutions, CROs, and academic laboratories. Inconsistent peptide purity introduces unquantifiable variables that undermine reproducibility and waste valuable grant resources.
PX1 Research manufactures CJC-1295 No DAC in domestic, cGMP-compliant facilities within the United States. Operations out of our California and Arizona logistics hubs enable same-day fulfillment (Monday through Friday), ensuring rapid transit times and minimal exposure to adverse temperatures.
For high-throughput screening, multi-animal cohorts, or long-term longitudinal studies, PX1 Research provides volume procurement options. Principal investigators and laboratory procurement managers can establish bulk growth factor research peptides accounts to secure lot reservation, custom vial sizes, and batch-specific analytical documentation tailored to institutional standards.
What is CJC-1295 No DAC (Mod GRF 1-29)?
CJC-1295 No DAC, also known as Modified GRF 1-29, is a 29-amino acid tetrasubstituted peptide analog of Growth Hormone Releasing Hormone (GHRH). It is designed for laboratory research to study pulsatile GH release and receptor kinetics without long-acting albumin binding.
How does Mod GRF 1-29 differ from CJC-1295 with DAC?
Mod GRF 1-29 lacks the Drug Affinity Complex (DAC). Without DAC, the peptide has a half-life of approximately 30 minutes, allowing pulsatile GH release. CJC-1295 with DAC binds to serum albumin, extending its half-life to several days and producing continuous baseline GH elevation.
What purity standard does PX1 Research guarantee for CJC-1295 No DAC?
PX1 Research guarantees a minimum purity of 99.0% verified by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and mass spectrometry for every production lot.
Are Certificates of Analysis (COA) provided with purchases?
Yes. Every shipment includes or provides access to a lot-specific COA detailing HPLC purity profiles, mass spec verification, and LAL endotoxin test results (<0.5 EU/mg).
How should lyophilized CJC-1295 No DAC be stored in the lab?
Lyophilized vials should be stored at -20°C for short-term preservation or -80°C for extended storage. Avoid ambient light and minimize freeze-thaw cycles once reconstituted.
What solvents are recommended for reconstituting Mod GRF 1-29?
Laboratory reconstitution typically utilizes sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS), depending on the requirements of the in vitro or in vivo model system.
Is CJC-1295 No DAC approved for human consumption or medical therapy?
No. CJC-1295 No DAC is strictly supplied as a scientific reagent for laboratory research, in vitro assays, and preclinical animal studies. It is strictly not for human or clinical use.
Why is CJC-1295 No DAC often paired with Ipamorelin in research literature?
In preclinical research, pairing a GHRH analog (Mod GRF 1-29) with a GHSR-1a agonist (Ipamorelin) produces synergistic GH release by concurrently activating separate intracellular signaling pathways (cAMP and IP3/calcium).
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.